Literature DB >> 27265007

Imatinib mesylate and the management of chronic myeloid leukemia (CML).

Ebru Koca, İbrahim C Haznedaroğlu.   

Abstract

Entities:  

Year:  2005        PMID： 27265007

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN： 1300-7777            Impact factor:   1.831


× No keyword cloud information.
  2 in total

1.  Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.

Authors:  Yusuf Baran; Jacek Bielawski; Ufuk Gunduz; Besim Ogretmen
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-11       Impact factor: 4.553

2.  Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.

Authors:  B Uz; O Bektas; E Eliacık; H Goker; Y Erbilgin; M Sayitoglu; N Sayinalp; S Aksu; Y Buyukasik; O Ozcebe; I C Haznedaroglu
Journal:  Case Rep Hematol       Date:  2011-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.